2+ week, 6+ day ago   (495+ words) The study, published in The Breast, evaluated whether chemotherapy selection supported by the Oncotype DX recurrence score was associated with differences in overall survival compared with physician-directed chemotherapy decisions without genomic testing. The findings highlight the growing role of genomic…...

1+ mon, 4+ day ago   (142+ words) Oncodaily Charles Jiang and Paolo Tarantino: Requirements for Validating ctDNA and MRD Biomarker Strategies in Breast Cancer Charles Jiang, Assistant Professor medical oncologist at UT Southwestern Medical Center, shared an update from Paolo Tarantino, Visiting Professor at McGill University Health…...

1+ mon, 1+ week ago   (597+ words) A shorter course of locoregional radiotherapy did not increase the risk of arm lymphedema or compromise cancer outcomes among patients with high-risk breast cancer, according to findings from the randomized Phase III Danish Breast Cancer Group Skagen Trial 1. The study…...

1+ mon, 2+ week ago   (193+ words) Ravindra Kolhe, Professor Of Pathology at Medical College of Georgia at Augusta University, shared on LinkedIn: “Only 7% of eligible patients with metastatic breast cancer (mBC) receive comprehensive genomic profiling. The bottleneck isn’t the technology-it’s systemic. In our newly published consensus…...

1+ mon, 2+ week ago   (282+ words) Oncodaily Evandro de Azambuja: CHMP Recommends Sacituzumab Govitecan + Pembrolizumab for mTNBC Evandro de Azambuja, President of the Belgian Society of Medical Oncology (BSMO) for 2023-2026, shared on LinkedIn: “CHMP recommends sacituzumab govitecan plus pembrolizumab for first-line PD-L1-positive metastatic TNBC The…...

2+ mon, 2+ hour ago   (132+ words) Humaid Al-Shamsi: Burjeel Cancer Institute’s Global Milestone in Administering Camizestrant for Advanced Breast Cancer Oncodaily Humaid Al-Shamsi: Burjeel Cancer Institute’s Global Milestone in Administering Camizestrant for Advanced Breast Cancer Humaid Al-Shamsi, The Chairman of Nexomic, shared on LinkedIn: “Precision oncology…...

2+ mon, 5+ day ago   (82+ words) David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on LinkedIn: “Cross-specialty discussion with my colleague Paolo Tarantino during this Peer View session. We focused…...

2+ mon, 2+ week ago   (274+ words) Below is a selection of the 10 papers, each offering unique insights into emerging discoveries, innovative therapeutic strategies, and evolving concepts that are shaping the future of cancer research and patient care. “At 200+ years, the bowhead whale outlives every other mammal…...

2+ mon, 2+ week ago   (294+ words) Olubukola Ayodele, Breast Cancer Lead at University Hospitals of Leicester NHS Trust, shared a post on LinkedIn: “One of the hardest realities in metastatic triple negative breast cancer is that some patients never receive a second line of therapy. The…...

3+ mon, 2+ week ago   (136+ words) Chadi Nabhan, hematologist and medical oncologist, Chief Medical Officer and Head of Strategy at Ryght, shared a post on LinkedIn: “Just as we all head to the annual ASCO26 meeting in Chicago, I am proud to share that the American Society…...